Blueprint Medicines gets more ducks in a row before CEO transition; Paul Stoffels has his work cut out for him at Gilead’s crumbling partner
→ When Jeff Albers announced he would no longer be CEO of Blueprint Medicines, the leadership carousel at the Aykakit maker had yet to wind down. Yes, Kate Haviland is next in line to replace Albers in April and Christina Rossi will succeed Haviland as COO, but who would fill Rossi’s position? The answers lies within the company again, as Philina Lee has been promoted to chief commercial officer and Helen Ho takes over CBO responsibilities.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.